At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 820 enrolled
Drug / intervention
ChimeriVax™-JE +1 morebiological
Likely dose
ChimeriVax™-JE 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Randomized, Double-blind, Phase III Study of The Comparative Immunogenicity, Safety and Tolerability of Two Japanese Encephalitis Vaccines (ChimeriVax™-JE and JE-VAX®)
In Brief
A Phase 3 clinical trial evaluating ChimeriVax™-JE and JE-VAX® for Japanese Encephalitis. Completed, enrolled 820 participants across 10 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVaxTM-JE and JE-VAX to the respective homologous virus strain after completion of vaccination course.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Encephalitis
CountriesAustralia, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedApr 2006
Primary CompletionJun 2006
Study CompletionNov 2006
TodayJul 2026
First PostedApr 13, 2006
Enrollment StartNov 1, 2005
Primary CompletionJun 1, 2006
Study CompletionNov 1, 2006
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 20.2 years ago
Interventions
ChimeriVax™-JEbiological
0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
JE-VAX®biological
0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)